October 18 - 22, 2015
Global experts explore the biology of globin gene regulation and fetal hemoglobin induction; stem cell transplant, gene therapy strategies, and gene editing; and clinical issues in thalassemia treatment and imaging.
Thursday, October 24, 2013 | 8:30 AM - 7:00 PM
Speakers: Charles H. Adler (Mayo Clinic Arizona / Arizona Parkinson's Disease Consortium), Raymond Bartus (RTBioconsultants, Inc.), Donald E. Frail (AstraZeneca PLC), Reina Fuji, VMD (Genentech Inc.), Kimberley S. Gannon (NeuroPhage Pharmaceuticals, Inc.), Kenneth Marek (Institute for Neurodegenerative Disorders), Mary Maral Mouradian (Rutgers - Robert Wood Johnson Medical School), Adrian Newman-Tancredi (Neurolixis, Inc.), Michael A. Schwarzschild (Massachusetts General Hospital), Eric Siemers (Eli Lilly and Company), Peggy Taylor (Covance Inc.)
Explore emerging basic and translational research that impacts our understanding of Parkinson's Disease and its treatment.
Monday, June 24, 2013 | 10:30 AM - 3:00 PM
Speakers: Yasmine Belkaid (National Institute of Allergy and Infectious Diseases, NIH), Dan R. Littman (New York University School of Medicine), Alexander Rudensky (Memorial Sloan-Kettering Cancer Center)
The Ross Prize, established in conjunction with the Feinstein Institute for Medical Research and Molecular Medicine, is awarded to an investigator producing innovative, paradigm-shifting research worthy of significant attention in molecular medicine.
Tuesday, March 12, 2013 | 8:30 AM - 4:30 PM
Speakers: Sheng Bi (Johns Hopkins University School of Medicine), Sheila Collins (Sanford-Burnham Medical Research Institute, Diabetes and Obesity Research Center), Abdul G. Dulloo (University of Fribourg), Vicente Gilsanz (Children's Hospital Los Angeles), Andrew C. Larner (Virginia Commonwealth University), David A. Price, Pfizer, Inc, Devanjan Sikder (Sanford-Burnham Medical Research Institute, Diabetes and Obesity Research Center), J. Enrique Silva (Tufts University School of Medicine), Bruce M Spiegelman (Dana-Farber Cancer Institute, Harvard Medical School), Anne-Ulrike Trendelenburg (Novartis Institutes for BioMedical Research, Yu-Hua Tseng (Joslin Diabetes Center, Harvard Medical School), Richard L. Veech (National Institute on Alcohol Abuse and Alcoholism/NIH)
This conference will present recent research exploring adipogenesis focusing on brown adipose tissue, and will explore its implications in diet-induced obesity.
June 26 - 27, 2012
Organizers: William G. Kerr (SUNY Upstate Medical University), Christina Mitchell (Monash University, Australia), and Christian Rommel (Intellikine)
Keynote Speaker: Lewis C. Cantley (Harvard Medical School)
Examine the role of Inositol Phospholipid (IP) signaling in cancer, metabolic, and inflammatory disease. This exploration of the specificity and interplay of diverse IP-modifying enzymes aims to identify novel approaches for therapeutic intervention.
Edited by Mone Zaidi
(Mount Sinai School of Medicine, New York, New York)
A new series in Annals, MARROW presents cutting-edge manuscripts on basic, translational, and clinical bone and bone marrow biology and medicine.
Edited by Annals of the New York Academy of Sciences
This Annals volume presents two meeting reports: (1) Influencing circadian and sleep–wake regulation for prevention and intervention in mood and anxiety disorders: what makes a good homeostat?; and (2) One Medicine One Science: a framework for exploring challenges at the intersection of animals, humans, and the environment.
Edited by Robert Giuli
(Deputy Director of OESO, Executive Director of the OESO Foundation, Paris, France) and Asad Umar
(National Cancer Institute, Rockville, Maryland)
This Annals volume presents a compilation of expert views on topics related to esophageal cancers presented at the World Organization for Specialized Studies on Diseases of the Esophagus 12th World Conference.
Edited by Rexford S. Ahima
(University of Pennsylvania, Philadelphia, Pennsylvania) and Alvin C. Powers
(Vanderbilt University, Nashville, Tennessee)
This Annals volume presents scholarly reviews by leading experts in diabetes and obesity research.
October 27, 2009
What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.
Translational Medicine Initiative
The Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.
Learn more at www.nyas.org/TransMed.